<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99270">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079558</url>
  </required_header>
  <id_info>
    <org_study_id>IRHRC-021</org_study_id>
    <secondary_id>JANU2014TAHERIPANAH</secondary_id>
    <nct_id>NCT02079558</nct_id>
  </id_info>
  <brief_title>Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section</brief_title>
  <official_title>Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti Medical University</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum hemorrhage (PPH) is a common complication of childbirth and a leading cause of
      maternal morbidity and mortality. The prompt and effective treatment of subjects with PPH
      would reduce operation risks. Hence in this study, the efficacy of Oxytocin and Carbetocin
      was compared in prevention of postpartum hemorrhage after cesarean sections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>screening of Cessation of bleeding</measure>
    <time_frame>screening until 24 hours after placenta disconnection</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>time duration to stop bleeding in the case of post-cesarean section</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 100 microgram IV dose of carbetocin after operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard 30 international units (IU) IV infusion of oxytocin during two hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Carbetocin with single 100 microg IV dosage was used in this investigation</description>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Duratocin,</other_name>
    <other_name>Pabal,</other_name>
    <other_name>Lonactene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin with 30 international units (IU) IV infusion was used in this investigation</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one risk for postpartum hemorrhage and lack of hypersensitivity to oxytocin
             and carbetocin

        Exclusion Criteria:

          -  Patients' refusal to cooperate, major therapeutic side effects, history of cardiac
             and renal disease or preeclampsia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robabeh Taheripanah, MD-Gyn.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infertility and Reproductive health Research center, Imam Hossien hospital, Shahid Beheshti Medical university, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infertility and Reproductive Health Research Center</name>
      <address>
        <city>Tehran</city>
        <zip>1985717443</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti Medical University</investigator_affiliation>
    <investigator_full_name>Dr Robabeh Taheripanah</investigator_full_name>
    <investigator_title>Associated prof. Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>cesarean section</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
